NCT03133676View on ClinicalTrials.gov

A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

April 28, 2020

Study Completion Date

April 28, 2020

Conditions
Osteoarthritis, Knee
Interventions
DRUG

KA34

50 µg - 400 µg intra-articular injection (single or multiple doses)

DRUG

Placebo

50 µg - 400 µg intra-articular injection (single or multiple doses)

Trial Locations (4)

16635

Altoona Center for Clinical Research, Duncansville

32806

Bioclinica Research, Orlando

33765

Clinical Research of West Florida, Clearwater

94598

Diablo Clinical Research, Walnut Creek

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Calibr, a division of Scripps Research

OTHER

NCT03133676 - A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis | Biotech Hunter | Biotech Hunter